University of Pennsylvania (UPenn)
Welcome,         Profile    Billing    Logout  
 9 Trials 
4 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Clark, Amy
ReTRIACt, NCT05579327 / 2022-001478-78: Withdrawal of Tiratricol Treatment in Males with Monocarboxylate Transporter 8 Deficiency (MCT8 Deficiency)

Recruiting
3
16
Europe, US
Tiratricol, Placebo
Rare Thyroid Therapeutics International AB, Premier Research Group plc, Egetis Therapeutics
Monocarboxylate Transporter 8 Deficiency, Allan-Herndon-Dudley Syndrome
04/25
06/25
AVIATOR, NCT03414658: The Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer

Hourglass Mar 2019 - Dec 2019 : From trial for cancer (unspecified)
Active, not recruiting
2
100
US
Vinorelbine, Trastuzumab, Avelumab, Utomilumab
Adrienne G. Waks, Pfizer, Breast Cancer Research Foundation, Johns Hopkins University
Breast Cancer
05/23
05/25
Saci-IO HR+, NCT04448886: Sacituzumab Govitecan +/- Pembrolizumab in HR+ / HER2 - MBC

Hourglass Jan 2021 - Jan 2021 : Data from trial for HR+ / HER2 – metastatic breast cancer
Active, not recruiting
2
110
US
Pembrolizumab, Keytruda, Sacituzumab Govitecan, TRODELVY
Ana C Garrido-Castro, MD, Merck Sharp & Dohme LLC, Gilead Sciences
Invasive Breast Cancer, Metastatic Breast Cancer, HR-Positive Breast Cancer, HER2-negative Breast Cancer
03/24
06/27
TBCRC 050, NCT03368729: Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer

Active, not recruiting
1/2
46
US
Niraparib, formerly MK-4827, Trastuzumab
University of Alabama at Birmingham, Translational Breast Cancer Research Consortium, Tesaro, Inc., Susan G. Komen Breast Cancer Foundation, Breast Cancer Research Foundation of Alabama, The V Foundation
Metastatic Breast Cancer, HER2 Positive Breast Carcinoma
11/26
12/26

Download Options